[go: up one dir, main page]

WO2008032056A3 - Marqueurs pour maladie - Google Patents

Marqueurs pour maladie Download PDF

Info

Publication number
WO2008032056A3
WO2008032056A3 PCT/GB2007/003447 GB2007003447W WO2008032056A3 WO 2008032056 A3 WO2008032056 A3 WO 2008032056A3 GB 2007003447 W GB2007003447 W GB 2007003447W WO 2008032056 A3 WO2008032056 A3 WO 2008032056A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
markers
dopamine receptor
interacting proteins
receptor interacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/003447
Other languages
English (en)
Other versions
WO2008032056A2 (fr
Inventor
Jamal Nasir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genophrenix Ltd
Original Assignee
Genophrenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618245A external-priority patent/GB0618245D0/en
Priority claimed from GB0708703A external-priority patent/GB0708703D0/en
Application filed by Genophrenix Ltd filed Critical Genophrenix Ltd
Publication of WO2008032056A2 publication Critical patent/WO2008032056A2/fr
Publication of WO2008032056A3 publication Critical patent/WO2008032056A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de diagnostic d'une maladie ou de détermination d'une prédisposition à une maladie chez un sujet, le procédé comprenant la détermination de la présence ou de l'absence d'une forme variante d'une ou de plusieurs des séquences d'acide nucléique représentées sur les Figures (1 à 11) dans un échantillon isolé où la présence d'un variant indique une maladie ou une sensibilité à une maladie.
PCT/GB2007/003447 2006-09-16 2007-09-13 Marqueurs pour maladie Ceased WO2008032056A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0618245A GB0618245D0 (en) 2006-09-16 2006-09-16 Markers for disease
GB0618245.5 2006-09-16
GB0708703A GB0708703D0 (en) 2007-05-04 2007-05-04 Markers for disease
GB0708703.4 2007-05-04

Publications (2)

Publication Number Publication Date
WO2008032056A2 WO2008032056A2 (fr) 2008-03-20
WO2008032056A3 true WO2008032056A3 (fr) 2008-07-17

Family

ID=38962811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003447 Ceased WO2008032056A2 (fr) 2006-09-16 2007-09-13 Marqueurs pour maladie

Country Status (1)

Country Link
WO (1) WO2008032056A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015639A1 (fr) * 1997-09-19 1999-04-01 Mcgill University Gene polymorphe contenant des unites de repetition cag et ses utilisations
WO2006043081A2 (fr) * 2004-10-21 2006-04-27 Genophrenix Ltd Technique de criblage
WO2006066121A2 (fr) * 2004-12-16 2006-06-22 Janssen Pharmaceutica N.V. Combinaison d'un inhibiteur de transporteur glycine (glyt1) et d'un antipsychotique destinee au traitement de symptomes de la schizophrenie ainsi que la preparation et l'utilisation de ce compose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015639A1 (fr) * 1997-09-19 1999-04-01 Mcgill University Gene polymorphe contenant des unites de repetition cag et ses utilisations
WO2006043081A2 (fr) * 2004-10-21 2006-04-27 Genophrenix Ltd Technique de criblage
WO2006066121A2 (fr) * 2004-12-16 2006-06-22 Janssen Pharmaceutica N.V. Combinaison d'un inhibiteur de transporteur glycine (glyt1) et d'un antipsychotique destinee au traitement de symptomes de la schizophrenie ainsi que la preparation et l'utilisation de ce compose

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE PROBE [online] 1 March 2006 (2006-03-01), XP002467887, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/GENOME/PROBE/REPORTS/PROBEREPORT.CGI?UID=4979804 *
DATABASE PROBE [online] 1 March 2006 (2006-03-01), XP002467889, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/GENOME/PROBE/REPORTS/PROBEREPORT.CGI?UID=4979818 *
DATABASE SNP [online] 10 August 2004 (2004-08-10), XP002467890, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/SNP/SNP_SS.CGI?SUBSNP_ID=23623867 *
DATABASE SNP [online] 5 November 2003 (2003-11-05), XP002467891, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/SNP/SNP_REF.CGI?RS=10150646 *
DATABASE SNP 5 November 2003 (2003-11-05), XP002467888, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/SNP/SNP_RETRIEVE.CGI?SUBSNP_ID=14010355 *
JOO E -J ET AL: "Possible association between schizophrenia and a CAG repeat polymorphism in the spinocerebellar ataxia type 1 (SCA1) gene on human chromosome 6p23", PSYCHIATRIC GENETICS, vol. 9, no. 1, March 1999 (1999-03-01), pages 7 - 11, XP009095551, ISSN: 0955-8829 *
NEVES-PEREIRA M ET AL: "BDNF gene is a risk factor for schizophrenia in a Scottish population", MOLECULAR PSYCHIATRY, vol. 10, no. 2, February 2005 (2005-02-01), pages 208 - 212, XP002469767, ISSN: 1359-4184 *

Also Published As

Publication number Publication date
WO2008032056A2 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
EP2177614A3 (fr) Composition et procédé permettant de diagnostiquer un cancer oesophagien et une métastase d'un cancer oesophagien
WO2010129937A3 (fr) Méthodes de détection de variations génétiques dans des échantillons d'adn
WO2008148072A3 (fr) Variations genetiques liees a une maladies et methodes de detection et d'utilisation de ces variations
WO2010039809A3 (fr) Amorces et sondes pour la détection du papillomavirus humain et des séquences de bêta globine humaine dans des échantillons test
GB0510943D0 (en) Improved immunoassay methods
EP2034324A3 (fr) Cartouche capteur
WO2008105896A3 (fr) Détermination d'analytes au moyen de réactifs de marquage de masse comprenant une étiquette détectable non encodée
WO2010148391A3 (fr) Analyse par biomarqueurs d'une pathologie neurologique
WO2008096225A3 (fr) Coffret et procédé de détection de médicament
WO2008082713A3 (fr) Matrice biologique à semi-conducteurs intégrés
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
EP2021794B8 (fr) Utilisation de la protéine s100a 12 en tant que marqueur du cancer du côlon et du rectum
WO2009055382A3 (fr) Dosages immunologiques en une étape présentant une sensibilité et une spécificité accrues
WO2010129354A3 (fr) Compositions et procédés de détection d'une prédisposition à un trouble d'utilisation de substance
WO2008128043A3 (fr) Procédés de diagnostic et de pronostic pour des carcinomes de cellules rénales
WO2008124091A3 (fr) Compositions et procédés de détection
WO2004057336A3 (fr) Utilisation de la nicotinamide n-methyltransferase comme marqueur du cancer colorectal
WO2008020823A3 (fr) Systèmes de rapporteur coopératifs, composants, et procédés pour une détection d'analyte
WO2009007649A3 (fr) Dispositif et procede d'identification et de determination de groupes sanguins
WO2008131261A3 (fr) Biomarqueurs peptidiques de maladie cardiovasculaire
WO2005124356A3 (fr) Utilisation d'une proteine cbp2 en tant que marqueur pour un cancer colorectal
WO2008003024A3 (fr) Procédé et composition destinés au diagnostic d'un cancer de l'endomètre
WO2007030949A3 (fr) Procedes de diagnostic de cancer des ovaires et necessaires a cet effet
WO2006119326A3 (fr) Compositions de sondes/amorces oligonucleotidiques et procedes de detection de polynucleotides
WO2007030373A3 (fr) Procede d'analyse d'hybridation in situ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804241

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804241

Country of ref document: EP

Kind code of ref document: A2